-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
RBOT:NYE- (USD)
COMMON STOCK | Medical Devices |
Last Closing
USD 6.67Change
-0.75 (-10.11)%Market Cap
USD 0.04BVolume
0.03MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Devices |
Last Closing
USD 6.67Change
-0.75 (-10.11)%Market Cap
USD 0.04BVolume
0.03MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ABT | Abbott Laboratories |
N/A |
USD 180.76B |
SYK | Stryker Corporation |
N/A |
USD 130.53B |
BSX | Boston Scientific Corp |
N/A |
USD 114.25B |
MDT | Medtronic PLC |
N/A |
USD 103.92B |
EW | Edwards Lifesciences Corp |
N/A |
USD 54.78B |
PHG | Koninklijke Philips NV ADR |
N/A |
USD 24.72B |
ZBH | Zimmer Biomet Holdings Inc |
N/A |
USD 22.08B |
STE | STERIS plc |
N/A |
USD 21.56B |
SNN | Smith & Nephew SNATS Inc |
N/A |
USD 11.07B |
GMED | Globus Medical |
N/A |
USD 9.19B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
BASE:CA | Evolve Global Materials &.. | 5.33 % | 0.00 % |
N/A |
CAD 0.05B |
BASE-B:CA | Evolve Global Materials &.. | 5.33 % | 0.00 % |
N/A |
CAD 0.08B |
HAP | VanEck Natural Resources .. | 2.22 % | 0.50 % |
N/A |
USD 0.13B |
RPAR | RPAR Risk Parity ETF | 0.72 % | 0.00 % |
N/A |
USD 0.62B |
SCID | 0.51 % | 0.39 % |
N/A |
N/A | |
JPEU | 0.46 % | 0.40 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -39.42% | 18% | F | 3% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -39.42% | 18% | F | 3% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -87.92% | 3% | F | 1% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -87.92% | 3% | F | 1% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -44.84% | 3% | F | N/A | F | ||
Dividend Return | -44.84% | 3% | F | N/A | F | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 37.00% | 52% | F | 27% | F | ||
Risk Adjusted Return | -121.17% | 6% | D- | 1% | F | ||
Market Capitalization | 0.04B | 9% | A- | 15% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total free cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector